1University of Leeds, M Sc Biotechnology, UK
2West Virginia University, USA
*Corresponding author: Ajay Dhakal, Clinical Fellow, Department of Medicine, Roswell Park Cancer Institute, University at Buffalo, Elm and Carlton Streets, 14263, Buffalo, New York, USA
Submission: July 31, 2017; Published: September 05, 2017
Thisreview aims at giving an insight at some of the recent approaches in using the aptamer technology in formulating the chemotherapeutic agent, doxorubicin, so as to achieve its targeted delivery and reduce its non-specific cytotoxicity.
Abbreviations: SELEX: Systematic Evolution Of Ligands By Exponential Enrichment; DOX: Doxorubicin; PSMA: Prostate-Specific Membrane Antigen; EpCAM: Epithelial Cell Adhesion Molecule; NPs: Nanoparticles; SPIONs: Superparamagnetic iron oxide nanoparticles; MRI: Magnetic Resonance Imaging; QDs: Quantum Dots; MUC1: Mucin 1; PSMA: Anti-Prostate Specific Membrane Antigen; TLC: Thermally Cross-Linked